Thought Leadership

Hear From Our Team of Experts

Amplity Health is a leader in the healthcare industry

From healthcare training to commercial solutions, Amplity’s position in the life science ecosystem affords us first-hand access to trends and market developments to provide value-added answers to your commercialization strategy challenges. Our clients rely on our timely, relevant, and insightful thought leadership when making medical or commercial decisions. As a contract commercial organization with decades of experience, you can count on us for valuable global healthcare solutions.

  • Answering the ‘why, when, what and who’ when launching a Companion Diagnostic

    NEW February 2021: The four simple areas that must be considered when launching a precision medicine therapy
    Read More
  • Medical Affairs in a Post-COVID Environment:
    A New Customer Engagement Model

    January 2021: A white paper shedding new light on the accelerated shift to digital engagement in Medical Affairs
    Read More
  • Laboratory Science Liaisons Support Novel Biomarker Testing for New Companion Diagnostic Case Study

    NEW January 2021: How Amplity helped a global Oncology pharma company establish their brand as a leader in Precision Medicine
    Read More
  • COVID-19 Trends in the Amplity Real-World Research Database

    November 2020: An exclusive look into COVID-19 findings the Amplity Insight’s team surfaced from their healthcare provider and patient interaction records. These records provide a proprietary level of detail, available nowhere else in the life science industry. The White Paper delves into the demographics, symptoms, comorbidities, and COVID-19 risk factors, and treatments received by patients who either had a confirmed COVID-19 diagnosis (positive or negative) or who had at least 3 symptoms consistent with COVID-19 in 2020 and provides insights on each.
    Read More
  • Why Amplity is Pharma’s Virtual Partner of Choice

    NEW January 2021: The COVID-19 pandemic has forever changed the way the pharmaceutical industry engages with healthcare providers. We know your sales and medical teams have lost traction and that an effective remote engagement strategy is critical to your sustained success. Click here to stream or below to download a short video to learn how Amplity Health has been a partner to large and small pharmaceutical companies for decades, helping them establish remote and blended engagement models for their teams. Tailored to your specific needs, our flexible Remote Engagement services and Capabilities Development training provide the new tools and skills needed to communicate in a virtual environment. Even if you’re not fully comfortable with implementing a 100% hybrid model, Amplity Health can be your guide as we leverage our industry-leading expertise and insights, working together seamlessly as true partners. We’ll be with you every step of the way, acting on your behalf as an extension of your team. Our pull through and dedication to true partnership is the reason why our client’s choose Amplity Health, and is the foundation for long-lasting, mutually beneficial relationships. Our client-first approach means that we intuitively and proactively seek our potential problems before they arise. We go above and beyond execution, as we deliver results and amplify the performance of your teams.
    Read More
  • Amplity’s Blended Engagement Model
    A New Post-COVID Health Care Provider (HCP) Customer Engagement Model for Pharma

    The COVID pandemic has been the catalyst to change the way the pharmaceutical industry (Pharma) engages with HCPs. Partnering with large and small pharma alike, this whitepaper explores Amplity's flexible model tailored to each customer’s needs leveraging the benefits of remote and in-person promotion, optimizing the promotional mix across personal and non-personal channels, and ultimately providing relevant, timely, and credible information to HCPs.
    Read More
  • The Salesforce of the Future

    COVID-19 has driven vast changes in what healthcare providers need and value from pharma companies, and as a result, the industry is striving to develop new ways to engage with physicians. Experts say this is just the beginning of a long journey and as the health ecosystem continues to morph, so will pharma interactions with HCPs.
    Read More
  • Remote Engagement and Outsourcing Survey Results

    Remote Engagement and Outsourcing Survey Results
    Read More
  • Creating Value with Real World Data and Natural Language Processing

    Learn how we leverage our own technologies and processes to extract unique insights from unstructured Real World Data
    Read More
  • Focus on Rare Diseases and Orphan Drug Marketing

    Taken together, rare diseases afflict as many as 30 million Americans - nearly 10% of the US population. To date, as many as 8,000 rare diseases have been identified but only 5% of rare diseases currently have any FDA-approved drug treatment. Up to 80% of these disorders have a genetic origin; in fact, most are caused by defects in a single gene. Rare diseases take a large toll on children: • Approximately 50% of those affected by rare diseases are children • 30% of children with a rare disease will succumb to it before reaching 5 years of age • Rare diseases cause 35% of deaths occurring during the first 12 months of life Read this whitepaper to find out the current state-of-play, the strategy to meet the demand, and the human resources aggressively treating patients with a rare disease.
    Read More